NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions

Lymphoma, Large-Cell, AnaplasticEnteropathy-Associated T-Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Extranodal NK-T-CellLymphoma, T-Cell, Peripheral

Interventions

BIOLOGICAL

Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells

Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

DRUG

Cyclophosphamide

300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

DRUG

Fludarabine

30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH